Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ralph Weichselbaum
University of Chicago, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Coordination Pharmaceuticals, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Weichselbaum has equity in Coordination Pharmaceuticals. Intellectual property (NCPs) that is licensed to Coordination Pharmaceuticals (Inventor is PI: Wenbin Lin) will be further developed and studied in the project for which he serves as Co-I. For this grant, Professor Lin proposes to develop robust nanoscale coordination polymers (NCPs) for the co-delivery of chemotherapeutic agents and small interfering RNA (siRNA) cocktails targeting multi-drug resistance pathways. NCPs carrying chemotherapeutic agents and siRNAs targeting these genes will be designed as personalized therapies for treating patients with metastatic colorectal cancer.
Targeted Nanomedicines with Synergistic Chemotherapeutics to Enhance Immunotherapy of Metastatic Colorectal Cancer
Project Narrative Metastatic colorectal cancer (mCRC) is the second leading cause of cancer-related deaths in the US, and CRC patients with distant metastasis have a 5-year survival rate of only ~12%. Current checkpoint blockade therapy does not benefit up to 95% of mCRC patients with MMR- proficient, microsatellite-stable disease. We propose to develop nanoscale coordination polymer-based, EGFR-targeted nanomedicines containing oxaliplatin and dihydroartemesinin (DHA) as an immune system booster to potentiate checkpoint blockade immunotherapy of mCRC.
Filed on June 18, 2019.
Tell us what you know about Ralph Weichselbaum's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Ralph Weichselbaum”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ralph Weichselbaum | University of Chicago | Conflict of Interest | Onosenescence | Value cannot be readily determined |
| Ralph Weichselbaum | University of Chicago | Conflict of Interest | RefleXion Medical | Value cannot be readily determined |
| Ralph Weichselbaum | University of Chicago | Conflict of Interest | RefleXion Medical | Value cannot be readily determined |
| Ralph Weichselbaum | University of Chicago | Conflict of Interest | RefleXion Medical | Value cannot be readily determined |
| Ralph Weichselbaum | University of Chicago | Conflict of Interest | Onosenescence | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.